Association of breast cancer outcome with status of p53 and MDM2 SNP309.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of the National Cancer Institute

• Publication date

  2006-07-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/DJJ245PMID 16818855
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.

  2006cited by this paper
• No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.

  2006cited by this paper
• Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.

  2006cited by this paper
• No Association Between the MDM2 −309 T/G Promoter Polymorphism and Breast Cancer in African-Americans or Whites

  2006cited by this paper
• The single nucleotide polymorphism IVS1+309 in mouse double minute 2 does not affect risk of familial breast cancer.

  2006cited by this paper
• Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans.

  2005cited by this paper
• A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells*

  2005cited by this paper
• Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.

  2005cited by this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cited by this paper
• The p53 pathway: positive and negative feedback loops

  2005cited by this paper
• Diet and alcohol consumption in relation to p53 mutations in breast tumors.

  2004cited by this paper
• SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• TP53 and breast cancer

  2003cited by this paper
• Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas

  2003cited by this paper
• p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.

  2003cited by this paper
• The MDM2-p53 interaction.

  2003cited by this paper
• The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

  2002cited by this paper
• The p53 and Mdm2 families in cancer.

  2002cited by this paper
• Polygenic susceptibility to breast cancer and implications for prevention

  2002cited by this paper
• The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node

  2002cited by this paper
• The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants.

  2001cited by this paper
• Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas.

  2000cited by this paper
• Alterations of p53 in tumorigenic human bronchial epithelial cells correlate with metastatic potential.

  1999cited by this paper
• Optimisation of DNA and RNA extraction from archival formalin-fixed tissue.

  1999cited by this paper
• The p53 pathway

  1999cited by this paper
• Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.

  1999cited by this paper
• Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

  1999cited by this paper
• Power and sample size calculations for studies involving linear regression.

  1998cited by this paper
• MDM2 in breast cancer

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Regulation of p53 stability by Mdm2

  1997cited by this paper
• TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.

  1995cited by this paper
• Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression.

  1995cited by this paper
• Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.

  1992cited by this paper
• Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

  1992cited by this paper
• Power and sample size calculations. A review and computer program.

  1990cited by this paper

• Ir-S Bonding Is Superior to Au-S Bonding for the Construction of Robust Antifouling Biosensors through Self-Assembly.

  2025cites this paper
• MDM2 Gene rs2279744 Polymorphism and Breast Cancer Risk: Evidence from Meta-Analysis and Meta-Regression Analysis

  2024cites this paper
• Diabetes-associated breast cancer is molecularly distinct and shows a DNA damage repair deficiency

  2023cites this paper
• Population-specific Mutation Patterns in Breast Tumors from African American, European American, and Kenyan Patients

  2023cites this paper
• Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types

  2023cites this paper
• The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review.

  2022cites this paper
• The MDM2 Single-Nucleotide Polymorphism T309G Is Associated With the Development of Epimacular Membranes

  2022cites this paper
• Genomic approach to identify association of environmental bisphenol-A (BPA) in daily use plastics as molecular disruptors in breast cancer

  2022cites this paper
• Benign single-nucleotide polymorphisms in the coding region of TP53: finding the needles in a haystack of pathogenic variants.

  2022cites this paper
• Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43

  2022cites this paper
• Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population

  2021cites this paper
• An NRP1/MDM2‐Targeted D‐Peptide Supramolecular Nanomedicine for High‐Efficacy and Low‐Toxic Liver Cancer Therapy

  2021cites this paper
• Murine Double Minute 2 Gene (MDM2) rs937283A/G variant significantly increases the susceptibility to breast cancer in Saudi Women

  2021cites this paper
• Differences in somatic TP53 mutation type in breast tumors by race and receptor status

  2021cites this paper
• A case‐control study on the SNP309T → G and 40‐bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer

  2020cites this paper
• Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study

  2019cites this paper
• Pharmacokinetic Study of Novel Anthraquinone Analogues

  2019cites this paper
• Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival

  2019cites this paper
• Genome-wide association study of germline variants and breast cancer-specific mortality

  2019cites this paper
• Evaluation of MALAT1 promoter DNA methylation patterns in early colorectal lesions and tumors

  2019cites this paper
• Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention

  2018cites this paper
• Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry

  2018cites this paper
• MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population

  2018cites this paper
• Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival

  2018cites this paper
• Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population

  2018cites this paper
• ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming

  2017cites this paper
• Association between single nucleotide polymorphisms of rs2279744 locus in MDM2 promoter region and risk of breast cancer: a Meta-analysis

  2017influential citation
• Germline determinants of colorectal cancer risk and outcome

  2017cites this paper
• The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

  2017cites this paper
• PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma

  2017cites this paper
• Lack of an Association between a Functional Polymorphism in the MDM2 Promoter and Breast Cancer in Women in Northeast Iran.

  2017cites this paper
• Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer

  2017cites this paper
• A PARP1 és p53 útvonal bioinformatikai és neuropatológiai vizsgálata gliomákban

  2017cites this paper
• Association between genetic variants in the promoter region of a novel antisense long noncoding RNA RP11‐392P7.6 and colorectal cancer risk

  2017cites this paper
• Associations between novel genetic variants in the promoter region of MALAT1 and risk of colorectal cancer

  2017cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• appendIX 1 assoCIatIon of the GermlIne MDM2 snp309 and TP53 r72p varIants WIth breast CanCer survival in sPeciFic tumor subgrouPs

  2017cites this paper
• Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy

  2016cites this paper
• Genetic Modifiers of the p53 Pathway.

  2016cites this paper
• THE CRISPR/CAS9-CREATED MDM2 T309G ENHANCES VITREOUS-INDUCED EXPRESSION OF MDM2 AND PROLIFERATION AND SURVIVAL OF CELLS

  2016cites this paper
• The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

  2016cites this paper
• Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma

  2016cites this paper
• The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells*

  2016cites this paper
• Breast Cancer: A Molecular and Redox Snapshot.

  2016cites this paper
• Clinical significance of TP53 (R72P) and MDM2 (T309G) polymorphisms in breast cancer patients

  2016cites this paper
• Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry

  2016cites this paper
• Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy

  2016cites this paper
• Sentinel Gene Within Cell Territory and Molecular Platforms in Cancer: Methylation Diversity of p53 Gene in Brain Tumors

  2015cites this paper
• Polymorphisms in NEIL-2, APE-1, CYP2E1 and MDM2 Genes are Independent Predictors of Gastric Cancer Risk in a Northern Jiangsu Population (China).

  2015cites this paper
• MDM2 (RS769412) G>A Polymorphism in Cigarette Smokers: a Clue for the Susceptibility to Smoking and Lung Cancer Risk.

  2015cites this paper
• MDM 2 ( RS 769412 ) G > a Polymorphism in Cigarette Smokers : A Clue for the Susceptibility to Smoking and Lung Cancer Risk

  2015cites this paper
• Phospho-histone H2AX is a diagnostic and prognostic marker for epithelial ovarian cancer.

  2015cites this paper
• TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

  2015cites this paper
• Association of MDM2 Polymorphism with Risk and Prognosis of Leukemia: A Meta-Analysis

  2015cites this paper
• Mutations of TP53 Gene and Oxidative Stress in Alzheimer’s Disease Patients

  2014cites this paper
• Cooperation of p53 mutations with other oncogenic alterations in cancer.

  2014cites this paper
• A quantitative LC-MS/MS method for determination of SP-141, a novel pyrido[b]indole anticancer agent, and its application to a mouse PK study.

  2014cites this paper
• Metabolic Profiles are Principally Different between Cancers of the Liver, Pancreas and Breast

  2014cites this paper
• Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls

  2014cites this paper
• Significance of MDM2-309 Polymorphisms and Induced Corresponding Plasma MDM2 Levels in Susceptibility to Laryngeal Squamous Cell Carcinoma

  2014cites this paper
• CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients

  2014cites this paper
• Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation

  2014cites this paper
• Association between the P53 codon 72 polymorphism and nasopharyngeal cancer risk

  2014cites this paper
• The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

  2014cites this paper
• Bringing p53 into the Clinic

  2014cites this paper
• MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.

  2014cites this paper
• Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart.

  2014cites this paper
• Mutations of TP 53 Gene and Oxidative Stress in Alzheimer ’ s Disease Patients

  2014cites this paper
• Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry

  2013cites this paper
• Assessing SNP-SNP Interactions among DNA Repair, Modification and Metabolism Related Pathway Genes in Breast Cancer Susceptibility

  2013cites this paper
• Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers.

  2013cites this paper
• Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome

  2013cites this paper
• Household Income Is Associated with the p53 Mutation Frequency in Human Breast Tumors

  2013cites this paper
• Identification of genetic markers with synergistic survival effect in cancer

  2013influential citation
• MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

  2013cites this paper
• Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator

  2013cites this paper
• Novel Connections Between DNA Replication, Telomere Homeostasis, and the DNA Damage Response Revealed by a Genome-Wide Screen for TEL1/ATM Interactions in Saccharomyces cerevisiae

  2013cites this paper
• Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.

  2012cites this paper
• Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry.

  2012cites this paper
• Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma

  2012cites this paper
• MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer

  2012cites this paper
• Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis

  2012cites this paper
• Genetic variants in TP53 and MDM2 associated with male infertility in Chinese population.

  2012cites this paper
• MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide

  2012cites this paper
• Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers

  2012influential citation
• Murine Double Minute Clone 2 309T/G and 285G/C Promoter Single Nucleotide Polymorphism as a Risk Factor for Breast Cancer: A Polish Experience

  2012cites this paper
• Stage T1 Urinary Bladder Carcinoma : Investigation of A Population-Based Cohort

  2012cites this paper
• Macrophages, Nitric Oxide and microRNAs Are Associated with DNA Damage Response Pathway and Senescence in Inflammatory Bowel Disease

  2012cites this paper
• STAGE T 1 URINARY BLADDER CARCINOMA : INVESTIGATION OF A POPULATION-BASED COHORT

  2012cites this paper
• MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis

  2011cites this paper
• MDM2 SNP309 contributes to tumor susceptibility: a meta-analysis.

  2011cites this paper
• Translational Research on Esophageal Cancer: From Cell Line to Clinic

  2011cites this paper
• MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.

  2011cites this paper
• Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups

  2011cites this paper
• No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.

  2011cites this paper
• MDM 2 SNP 309 modifies the prognostic significance of the p 53 mutational status in patients with ovarian cancer

  2011cites this paper
• MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis

  2011cites this paper
• Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy.

  2011cites this paper
• Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel

  2011cites this paper
• Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA

  2011cites this paper